Percutaneous Coronary Intervention (PCI) ProcedureDescription, Latest Information and Doctors
Learn About Percutaneous Coronary Intervention (PCI)
Georgia Heart Institute
Stephane Rinfret is an Interventional Cardiologist practicing medicine in Gainesville, Georgia. He has been practicing medicine for over 34 years. Dr. Rinfret is rated as an Elite provider by MediFind in Percutaneous Coronary Intervention (PCI). He is also highly rated in 10 other conditions, according to our data. His clinical expertise encompasses Heart Attack, Coronary Heart Disease, Acute Coronary Syndrome, Percutaneous Coronary Intervention (PCI), and Angioplasty. Dr. Rinfret is board certified in Royal College Of Physicians & Surgeons Canada, Cardiovascular Disease - 1998 and Royal College Of Physicians & Surgeons Canada, Internal Medicine - 1996. Dr. Rinfret is currently accepting new patients.
New York-Presbyterian/Columbia University Medical Center
Gregg Stone is a Cardiologist practicing medicine in New York,, New York. Dr. Stone is rated as an Elite provider by MediFind in Percutaneous Coronary Intervention (PCI). He is also highly rated in 27 other conditions, according to our data. His clinical expertise encompasses Heart Attack, Mitral Valve Regurgitation, Acute Coronary Syndrome, Percutaneous Coronary Intervention (PCI), and Heart Bypass Surgery.
Guggenheim Pavilion
George Dangas is a Cardiologist practicing medicine in New York, New York. Dr. Dangas is rated as an Elite provider by MediFind in Percutaneous Coronary Intervention (PCI). He is also highly rated in 45 other conditions, according to our data. His clinical expertise encompasses Coronary Heart Disease, Heart Attack, Aortic Valve Stenosis, Percutaneous Coronary Intervention (PCI), and Transcatheter Aortic Valve Replacement (TAVR).
Summary: This is a randomized, controlled study. ACS follow- up patients aged 18 to 80 years old with hemodynamic stability, who are 14 days to 1 year after PCI, are screened through the HAMD score and the HAMA score. Patients with a HAMD score greater than 7 points and a HAMD score higher than that of the HAMA, are included in this study. Patients were allocated to the active taVNS group or sham taVNS gro...
Summary: Patients receiving chronic oral anticoagulation with indication for percutaneous coronary revascularization with stent implantation, and needing for antiplatelet therapy, are at high risk of bleeding. The new generation of ultrathin strut sirolimus-eluting stent with bioabsorbable polymer allow for shorter antiplatelets regimens and could be a good option for this high-bleeding risk patients.